The story has been updated to provide additional details and comments from Adaptive Biotechnologies' CEO, Chad Robins.

NEW YORK (GenomeWeb News) – Immune sequencing services company Adaptive Biotechnologies has raised $5 million toward a targeted $20 million financing round.

In a Form D filed with the US Securities and Exchange Commission recently, it said that the securities offered were in the form of equity. Adaptive Bio's CEO Chad Robins told GenomeWeb Daily News that that the $5 million was the first tranche of a Series C round.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biologists turn to environmental DNA sampling to determine whether elusive or invasive species are shedding DNA in a given area.

Rob Knight writes at Scientific American that microbiome studies are about to break out of the laboratory.

Harold Varmus, the director of the National Cancer Institute, has announced that he is stepping down after nearly five years.

In Nature this week: omic analysis of permafrost microbes, hookworm genome, and more.